Azurix, 120 mg 30 pcs

Uric acid is the end product of purine metabolism in humans and is formed by the following reaction: hypoxanthine → xanthine → uric acid. Xanthine oxidase is a catalyst for both steps of this reaction. Febuxostat is a 2-arylthiazole derivative. Its therapeutic effect is associated with reduction of serum uric acid concentration by selective inhibition of xanthine oxidase. Febuxostat is a potent and selective non-purine xanthine oxidase inhibitor (NP-SIXO), its inhibition constant (Ki) is <1 nM. Febuxostat was shown to significantly inhibit the activity of both oxidized and reduced forms of xanthine oxidase. At therapeutic concentrations, febuxostat does not affect other enzymes involved in purine or pyrimidine metabolism, such as guanine deaminase, hypoxanthineguanine phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleoside phosphorylase.Clinical effectiveness and safety:

Indications

Treatment of chronic hyperuricemia in patients with diseases accompanied by deposition of urate crystals, including the presence of tophi and/or gouty arthritis currently or in history.

Pharmacological effect

Uric acid is the end product of purine metabolism in humans and is formed by the following reaction: hypoxanthine → xanthine → uric acid. Xanthine oxidase is the catalyst for both steps of this reaction. Febuxostat is a 2-arylthiazole derivative. Its therapeutic effect is associated with a decrease in the concentration of uric acid in the blood serum through selective inhibition of xanthine oxidase. Febuxostat is a potent and selective non-purine xanthine oxidase inhibitor (NP-SIXO) with an in vitro inhibition constant (Ki) of <1 nM. Febuxostat has been shown to significantly inhibit the activity of both the oxidized and reduced forms of xanthine oxidase. At therapeutic concentrations, febuxostat does not affect other enzymes involved in the metabolism of purines or pyrimidines, such as guanine deaminase, hypoxanthine guanine phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleoside phosphorylase. Clinical efficacy and safety:

Special instructions

Cardiovascular diseases

Active ingredient

Febuxostat

Contraindications

Hypersensitivity to the active substance or any other auxiliary component of the drug.

Side Effects

The most common adverse reactions in clinical studies (4072 patients using a dose of 10 to 300 mg) and during post-marketing surveillance in patients with gout were exacerbations (attacks) of gout, liver dysfunction, diarrhea, nausea, headache, rash and swelling. These reactions were in most cases mild to moderate in severity. During post-marketing surveillance, there have been reports of serious hypersensitivity reactions to febuxostat, some of which were accompanied by systemic reactions.

Interaction

Mercaptopurine/azathioprine. Due to the mechanism of action of febuxostat, which is its ability to inhibit xanthine oxidase, its simultaneous use with mercaptopurine/azathioprine is not recommended. Inhibition of xanthine oxidase may lead to increased plasma concentrations of both drugs, which may cause a toxic reaction. There have been no studies of the interaction of febuxostat with drugs that are metabolized by xanthine oxidase.

Overdose

In case of overdose, symptomatic and supportive therapy is indicated.

Storage conditions

Does not require special storage conditions.

Manufacturer

Alium JSC, Russia